Hoth Therapeutics (Hoth Therapeutics) Total Liabilities : $0.66 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics Total Liabilities?

Hoth Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $0.66 Mil.

Hoth Therapeutics's quarterly Total Liabilities declined from Sep. 2023 ($1.58 Mil) to Dec. 2023 ($0.71 Mil) and declined from Dec. 2023 ($0.71 Mil) to Mar. 2024 ($0.66 Mil).

Hoth Therapeutics's annual Total Liabilities increased from Dec. 2021 ($1.10 Mil) to Dec. 2022 ($1.64 Mil) but then declined from Dec. 2022 ($1.64 Mil) to Dec. 2023 ($0.71 Mil).

Hoth Therapeutics Total Liabilities Historical Data

The historical data trend for Hoth Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hoth Therapeutics Total Liabilities Chart

Hoth Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

0.44

0.60

1.10

1.64

0.71

Hoth Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1.60	1.97	1.58	0.71	0.66

Hoth Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Hoth Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.679	+	(0.026	+	-8.673617379884E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.71

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	9.52	-	8.815
	=	0.71

Hoth Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.64	+	(0.019	+	1.7347234759768E-17
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.66

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	8.491	-	7.833
	=	0.66

Hoth Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hoth Therapeutics (Hoth Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020

Website

https://www.hoththerapeutics.com

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Executives

Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie	director, officer: CEO and President	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns	officer: Chief Scientific Officer	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes	director	1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc	10 percent owner	725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr	director	C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones	officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner	10 percent owner	44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor	10 percent owner	750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern	10 percent owner	20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023